

Malignant Hematology Areas of Interest

(Investigator Initiated Studies and Research Collaborations)

REGN1979 (CD20xCD3) odronextamab

Non-interventional proposals:

1. Predictors of response and/or (primary or acquired) resistance to Odronextamab in the treatment of b-NHL, including Investigating immune correlates of response to CD20xCD3 bispecific antibodies in B-NHL

Interventional proposals:

1. Novel treatment combinations, including combinations with novel agents targeting non-redundant pathways, in all lines of therapy for the treatment of b-NHL.
2. Sequencing or optimization of treatment regimen (e.g., new outpatient administration/monitoring protocols)
3. Investigating Odronextamab in hard-to-treat, medically unaddressed, and rare populations with B-Cell malignancies in high unmet medical needs for treatment.

(6.0, Aug2025)

REGN5458 (BCMA x CD3) linvoseltamab

Clinical Interventional proposals:

1. Multiple Myeloma
 - a. Unique sequencing strategies with SOC and novel therapies across lines of therapy, including NDMM and early relapse
 - b. Novel treatment combinations
 - c. Strategies to improve the safety and tolerability profile
 - d. Optimization of treatment administration
 - e. Exploration in special patient subpopulations of high unmet need
2. Other plasma cell dyscrasias
3. BCMA targetable non-plasma cell dyscrasias

(v6.0, Jan2026)

Regeneron is currently accepting proposals for Investigator Initiated Studies and Research Collaborations for Malignant Hematology Products in North America, United Kingdom (UK) and the European Union (EU).